You are here

Bioiberica reaffirms its commitment to innovation with four new scientific publications in 2020

14 Feb 2020
  • The papers describe the use of various raw materials in cell regeneration and their regulatory aspects

Researchers from Bioiberica's Human Health R&D Department have published four new articles in high scientific impact journals in the first two months of 2020.

The papers present the results of experimental studies on the use of Bioiberica's hyaluronic acid for artificial cartilage bioprinting (1) and various regulatory and technical aspects on the use of cell cultures in advanced therapies (2, 3, 4).  

They are the result of Bioiberica's participation in the RETOS R&D consortia (RTC-2016-5451-1 financed by the Ministry of Economy and Competitiveness) and ADVANCECAT (within the RIS3CAT programme financed by ACCIÓ, the Agency for the Competitiveness of Enterprise of the Government of Catalonia, and by the European Union).

These papers are part of the new strategic plan for Innovation and Development of the company's Human Health area, currently focused on the therapeutic areas of Dermatology and Joint Health.



1- Bio-inspired hydrogel composed of hyaluronic acid and alginate as a potential bioink for 3D bioprinting of articular cartilage engineering constructs. Antich C, de Vicente J, Jiménez G, Chocarro C, Carrillo E, Montánez E, Gálvez-Martín P, Marchal JA. Acta Biomaterialia. DOI:

2- Role of mesenchymal stem cells as therapeutic agents: potential mechanisms of action and implications in their clinical use. Jimenez-Puerta GJ; Marchal JA; Lopez-Ruiz E; Gálvez-Martín P. J. Clin. Med. (F.I.: 5.688; D1).

3- A worldwide overview of regulatory frameworks for tissue-based products. Oberweis CMarchal JALópez-Ruiz EGalvez-Martin P. Tissue Eng Part B Rev. 2020 Jan 7. doi: 10.1089/ten.TEB.2019.0315. (F.I.: 6.512; D1).

4- An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: From laboratory to patient. López-Beas J, Guadix JA, Clares B, Soriano JL, Zugaza JL, Gálvez-Martín P. Med Res Rev. 2020;0–0. (F.I.: 9.791; D1).


Related News

3 Mar 2020
  • The company maintains, for another year, the "Good” rating
15 Apr 2019
  • The Profarma committee released their ratings for the pharmaceutical sector firms
  • Bioiberica keeps the “good” rating within the A Group (those companies with significant research activity and having their own production plant or basic/pre-clinical R&D center)